Study Goal: This study aims to understand how a drug called zigakibart affects a kidney disease known as IgA nephropathy (IgAN). IgAN causes kidney damage by building up a protein called IgA, which can lead to kidney problems over time.
This study will last up to 125 weeks (about 2.5 years) for each participant. Participants are split into two groups; one group will have a kidney biopsy (a small sample of kidney tissue taken for testing) after the first year, and the other group after the second year of treatment.
- Participants must have been diagnosed with primary IgAN within the last 5 years.
- The study requires several visits over about 2.5 years, including a follow-up period to ensure safety.
- Participants should not have other kidney diseases, untreated or hard-to-treat high blood pressure, or recent use of certain medications.
It's important to understand your condition and discuss with a doctor if this study might be right for you. The study requires commitment and will involve regular medical assessments.
How understandable was the trial content above?
Hard to understand
Easy to understand